Graft versus host disease (GvHD) is a condition that might occur after an allogeneic transplant. A condition that occurs when donor bone marrow or stem cells attack the recipient. Gvhd occur especially in immune-compromised patients. Radioactive agents or chemicals affect both the cancer cells and healthy cells during cancer treatment. The reconstruction of affected body cells can be done using stem cells and bone marrow transplant. The bone marrow is obtained from the donor through an infusion after a high dose of chemotherapy, which in turn help to resume the production of blood cells. GvHD occurs when certain white blood cells are not compatible with the existing cell type and, thus, the recipient’s body is attacked by the transplanted cells. The signs and symptoms of graft versus host disease are usually not too severe, although in some cases it can be fatal. Thus, cells of both the recipient and donor are closely screened and matched prior to the transplant to avoid the risk of Gvhd.
Ask for free Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/184
Increasing research and development (R&D) activities is expected to boost the growth of the global graft versus host disease (GvHD) market over the forecast period. The graft versus host disease (GvHD) market has evolved significantly in recent times with the introduction of small molecule immunosuppressant therapies (biological and patented). Moreover, the current R&D programs/activities are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. These programs/activities are characterized by an increasing trend towards maintaining an appropriate prophylactic regimen and inhibiting activation and proliferation of T-cell. Such regimens are used for hematopoietic stem cell transplantation and are tailored to the conditioning and transplant types. However, there is a great potential for risk of opportunistic infection during this process.
However, most R&D strategies/activities, including clinical studies regarding targeting niche subgroup under GvHD, such as steroid refractory cGVHD and aGVHD, are the major R&D strategies in the GVHD pipeline. Extensive R&D activities are expected to drive growth of the global graft versus host disease market during the forecast period.
Moreover, rise in need for GvHD management is also expected to aid in the global graft versus host disease market growth. There are currently few or no guidelines for GvHD management that can accurately maintain data from large populations suffering from GvHD, although some recommendations exist for such treatments.
Furthermore, graft versus host disease is orphan in nature, which may be one of the important factors influencing the treatment regimes and lack of guidelines. Lack of randomized clinical trials and non-popularity of Gvhd is another factor that is expected to hamper the growth of the market. This in turn has resulted in inappropriate clinical evidence, which are not comparable and not applicable to all GvHD patients. However, advancements in early detection process is expected to propel the global graft versus host disease market growth.
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐎 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/184
Market players are engaged in R&D to enhance the outcomes of the therapy, which in turn is also expected to aid in the growth of the market. For instance, in 2017, an international research team led by the University of Michigan Life Sciences Institute revised the understanding of the key cellular and molecular events that trigger GvHD.
Moreover, market players are focusing on launching novel products, as well as are adopting various strategies, such as merger and acquisition, to gain competitive edge in the market and to strengthen their product portfolio. For instance, in February 2017, Kalytera Therapeutics, Inc. announced that it has completed the previously announced acquisition of Talent Biotechs Ltd. to strengthen its position as an emerging market leader in cannabidiol pharmaceuticals.
Key players operating in the global graft versus host disease market are Novartis AG, Sanofi, Merck & Co., Astellas Pharma, Mesoblast Ltd., Soligenix, Inc., and Neovii Biotech GmbH, among others.
In May 2019, the Food and Drug Administration (FDA) approved ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory GvHD in adult and pediatric patients 12 years and older.
In November 2017, Merck & Co., Inc., received FDA approval for PREVYMIS (letermovir), once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for the patients suffering from GvHD.
In August 2017, Pharmacyclics LLC received FDA approval for Imbruvica (ibrutinib) drug, for the treatment of adult patients with chronic GvHD.
By Disease Type:
- Acute graft vs. host disease (aGvHD)
- Chronic graft vs. host disease (cGvHD)
By Product Type:
- Monoclonal antibodies
- mTOR inhibitors
- Tyrosine kinase inhibitors
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/184
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Graft Versus Host Disease (GvHD) Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Graft Versus Host Disease (GvHD) Industry Impact
Chapter 2 Graft Versus Host Disease (GvHD) Competition by Types, Applications, and Top Regions and Countries
2.1 Graft Versus Host Disease (GvHD) (Volume and Value) by Type
2.3 Graft Versus Host Disease (GvHD) (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Graft Versus Host Disease (GvHD) Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Graft Versus Host Disease (GvHD) Market Analysis
Chapter 6 East Asia Graft Versus Host Disease (GvHD) Market Analysis
Chapter 7 Europe Graft Versus Host Disease (GvHD) Market Analysis
Chapter 8 South Asia Graft Versus Host Disease (GvHD) Market Analysis
Chapter 9 Southeast Asia Graft Versus Host Disease (GvHD) Market Analysis
Chapter 10 Middle East Graft Versus Host Disease (GvHD) Market Analysis
Chapter 11 Africa Graft Versus Host Disease (GvHD) Market Analysis
Chapter 12 Oceania Graft Versus Host Disease (GvHD) Market Analysis
Chapter 13 South America Graft Versus Host Disease (GvHD) Market Analysis
Chapter 14 Company Profiles and Key Figures in Graft Versus Host Disease (GvHD) Business
Chapter 15 Graft Versus Host Disease (GvHD) Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027